Standard Operating Procedure for Compilation of Regional CMC Variants From Core Dossiers
| Department | Regulatory Affairs |
| SOP No. | RA/2026/720 |
| Supersedes | NA |
| Page No. | 1 of X |
| Issue Date | 14/04/2026 |
| Effective Date | 14/04/2026 |
| Review Date | 14/04/2028 |
Purpose
This Standard Operating Procedure (SOP) establishes a consistent and controlled method for compiling regional Chemistry, Manufacturing, and Controls (CMC) variants derived from core dossiers. The purpose is to ensure that all regional differences in regulatory requirements, product specifications, and submission content are accurately identified, documented, and incorporated to maintain compliance with applicable local regulations while preserving the integrity and consistency of the core dossier. This SOP supports regulatory compliance, mitigates risks associated with documentation errors, and facilitates timely and efficient dossier submissions.
Scope
This SOP applies to all activities related to the compilation, review, and maintenance of regional CMC variants derived from core dossiers affecting regulatory submissions for pharmaceutical products. It covers dossier variants for different dosage forms and presentations handled by Regulatory Affairs, Quality Assurance, and related departments involved in dossier preparation. The procedure encompasses differences in formulation details, manufacturing processes, specifications, stability data, and labeling as per regional requirements. This SOP excludes clinical, non-CMC regulatory documents, and post-approval change management processes that are governed by separate procedures.
Responsibilities
- Regulatory Affairs Specialists: Execute compilation and coordination of regional dossier variants aligned with regional regulatory requirements.
- Quality Assurance: Review and verify compliance aspects of compiled variants prior to submission.
- Documentation Control: Manage version control and archival of core dossiers and regional variants.
- Regulatory Managers: Supervise overall compilation activities and approve final dossiers.
- Subject Matter Experts (e.g., CMC, Engineering, QA): Provide technical inputs and validate differences impacting quality or compliance.
Accountability
The Head of Regulatory Affairs holds accountability for the implementation, compliance, periodic review, and escalation of issues related to this SOP. They ensure the SOP remains current, effective, and aligned with evolving regulatory requirements, guiding periodic training and ensuring audit readiness regarding dossier compilation activities.
Procedure
The compilation of regional CMC variants from core dossiers shall proceed according to the following steps:
- Preparation and Prerequisites:
- Confirm availability of the approved core dossier including all technical sections, batch records, validation data, and reference standards.
- Gather and review the relevant regional regulatory guidelines and specific CMC requirements for each target market.
- Identify authorized points of contact within regional RA and QA departments to collaborate on variant compilation.
- Gap Analysis and Variant Identification:
- Perform a comparative analysis to identify discrepancies between the core dossier and regional requirements, including differences in manufacturing sites, excipients, release specifications, stability protocols, and packaging.
- Document identified variations in a structured tracking tool specifying the nature, rationale, and required supporting documentation.
- Variant Compilation:
- Modify core dossier elements to develop the regional variant reflecting identified differences, ensuring all changes are traceable and justified.
- Confirm that CMC data, including batch formulas, analytical methods, and validation summaries, meet regional standards and formats.
- Coordinate cross-functional inputs from manufacturing, quality control, and engineering to validate technical adequacy of variants.
- Review and Verification:
- Internal review of the compiled regional variant by Regulatory Affairs and Quality Assurance teams to confirm compliance and completeness.
- Address any discrepancies or comments raised during review through controlled document revisions.
- Ensure that all changes are documented according to change control procedures.
- Approval and Documentation Control:
- Obtain necessary approvals from Regulatory Managers and Quality Heads prior to submission.
- Assign version numbers and maintain change logs reflecting updates to the core dossier and its regional variants.
- Archive all versions, approvals, and supporting documents in the Document Management System following company policies.
- Submission and Follow-up:
- Prepare regional submission packages inclusive of compiled variants for regulatory filings.
- Maintain communication with local health authorities and internal stakeholders for clarifications or amendments.
- Track and control feedback and inspection outcomes related to the submitted dossier variants.
- Deviations and Change Management:
- Investigate and document any deviations or unforeseen challenges encountered during compilation.
- Implement corrective actions in accordance with the company’s deviation management SOP.
- Update this SOP or related processes if recurrent issues or regulatory changes dictate process improvements.
- Training and Periodic Review:
- Ensure that all personnel involved are trained on this SOP and any updates.
- Conduct periodic reviews and audits to verify adherence and effectiveness of the compilation process.
- Collect and incorporate feedback to enhance continuous improvement.
Abbreviations
- CMC: Chemistry, Manufacturing, and Controls
- RA: Regulatory Affairs
- QA: Quality Assurance
- SOP: Standard Operating Procedure
- GMP: Good Manufacturing Practices
- DMS: Document Management System
Documents
Only documents directly relevant to the compilation of regional CMC variants from core dossiers are listed below:
- Regional CMC Variant Compilation Checklist (Annexure-1)
- Core Dossier Comparison Worksheet (Annexure-2)
- Approval and Change Log for Regional Dossier Variants (Annexure-3)
References
- ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
- EMA Guidelines on the Chemistry, Manufacturing and Control Documentation
- FDA Guidance for Industry: Chemistry, Manufacturing, and Controls Information
- Company Quality Management System Documentation Control Procedures
- Regional Health Authority Regulatory Guidelines and Requirements specific to respective markets
Version
1.0
Approval
| Prepared By | |
| Checked By | |
| Approved By |
Annexures
Annexure-1: Regional CMC Variant Compilation Checklist
Purpose: To provide a systematic checklist ensuring all key areas are reviewed and documented during the compilation of regional CMC dossier variants.
| Check Item | Status (Yes/No/NA) | Remarks |
|---|---|---|
| Core dossier availability and approval status | Yes | Core dossier V2.2 available |
| Identification of regional regulatory guidelines and requirements | Yes | Reviewed EMA and Health Canada requirements |
| Gap analysis completed between core and regional requirements | Yes | Completed on 10/04/2026 |
| Documentation of all CMC differences | Yes | |
| Technical inputs and cross-functional validation obtained | Yes | Inputs from QA and Manufacturing recorded |
| Review by Regulatory Affairs and QA completed | Yes | Reviewed on 12/04/2026 |
| Approvals obtained prior to submission | Pending | Awaiting Regulatory Manager signature |
| Version control and archiving confirmed | Yes | Document archived under DMS ref RA/2026/720 |
| Submission package prepared per local requirements | NA | To be completed post approval |
| Training on SOP provided to stakeholders | Yes | Training completed 11/04/2026 |
Annexure-2: Core Dossier Comparison Worksheet
Purpose: To document detailed differences identified between the core dossier and regional requirements to guide compilation of regional variants.
| Section | Core Dossier Detail | Regional Requirement | Difference Description | Action Required |
|---|---|---|---|---|
| Formulation Composition | Excipient X at 2% | Excipient X max 1.5% | Reduce excipient X concentration | Formulation adjustment & re-validation needed |
| Manufacturing Site | Site A only | Sites A and B accepted | Add manufacturing site B documentation | Include site B validation reports |
| Release Specification | Test A with limit 5-10% | Test A with limit 4-11% | Adjust specification limits | Revise certified specification sheets |
| Stability Data | Data for 24 months at RT | Require 36 months stability data | Obtain extended stability data | Initiate additional stability studies |
| Packaging Materials | Aluminium foil blister | Aluminium foil with moisture barrier | Upgrade blister foil properties | Update packaging specifications and validation |
Annexure-3: Approval and Change Log for Regional Dossier Variants
Purpose: To record all approval signatures, version control details, and change history related to compilation and submission of regional CMC dossier variants.
| Version | Date | Change Description | Prepared By | Checked By | Approved By |
|---|---|---|---|---|---|
| 1.0 | 14/04/2026 | Initial compilation of regional variants with documented differences and approvals pending |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
| 14/04/2026 | 1.0 | Initial issue | New SOP creation |